These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16938113)

  • 1. Soluble CD40 ligand levels during controlled ovarian hyperstimulation--a possible culprit of systemic inflammation.
    Orvieto R; Schachter B; Yulzari-Roll V; La Marca A; Bar J; Fisch B
    Am J Reprod Immunol; 2006 Oct; 56(4):243-8. PubMed ID: 16938113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian androgens but not estrogens correlate with the degree of systemic inflammation observed during controlled ovarian hyperstimulation.
    Orvieto R; Fisch N; Yulzari-Roll V; La Marca A
    Gynecol Endocrinol; 2005 Sep; 21(3):170-3. PubMed ID: 16335910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycles.
    Orvieto R; Yulzari-Roll V; La Marca A; Ashkenazi J; Fisch B
    Gynecol Endocrinol; 2005 Oct; 21(4):218-22. PubMed ID: 16316843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
    Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
    Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble L-selectin levels during controlled ovarian hyperstimulation.
    Orvieto R; Ben-Rafael Z; Schwartz A; Abir R; Fisch B; La-Marca A; Bar-Hava I
    Gynecol Endocrinol; 2001 Feb; 15(1):29-33. PubMed ID: 11293921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
    Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of urinary versus recombinant gonadotropin on serum P-selectin levels in vivo.
    Orvieto R; La Marca A; Badir W; Golan O; Bar J; Fisch B
    Gynecol Endocrinol; 2005 Apr; 20(4):185-7. PubMed ID: 16019359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle.
    Orvieto R; Chen R; Ashkenazi J; Ben-Haroush A; Bar J; Fisch B
    Hum Reprod; 2004 Feb; 19(2):357-9. PubMed ID: 14747180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled ovarian hyperstimulation--a state of endothelial activation.
    Orvieto R; Schwartz A; Bar-Hava I; Abir R; Ashkenazi J; La-Marca A; Ben-Rafael Z
    Am J Reprod Immunol; 2000 Nov; 44(5):257-60. PubMed ID: 11125785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum P-selectin level during controlled ovarian hyperstimulation--a preliminary report.
    Orvieto R; Badir W; Bar J; La Marca A; Ashkenazi J; Avrech OM; Fisch B
    Am J Reprod Immunol; 2004 Aug; 52(2):139-42. PubMed ID: 15274655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and follicular fluid leptin levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycle.
    Chen R; Fisch B; Ben-Haroush A; Kaplan B; Hod M; Orvieto R
    Clin Exp Obstet Gynecol; 2004; 31(2):103-6. PubMed ID: 15266760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled ovarian hyperstimulation--an inflammatory state.
    Orvieto R
    J Soc Gynecol Investig; 2004 Oct; 11(7):424-6. PubMed ID: 15458738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF.
    Manau D; Fábregues F; Peñarrubia J; Creus M; Carmona F; Casals G; Jiménez W; Balasch J
    Hum Reprod; 2007 Mar; 22(3):669-75. PubMed ID: 17079244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 production in whole blood cell cultures of women undergoing controlled ovarian hyperstimulation for assisted reproduction technology cycles.
    Orvieto R; Leites T; Abir R; Bar J; Yoeli R; Feldberg D; Fisch B
    Am J Reprod Immunol; 2003 Sep; 50(3):220-3. PubMed ID: 14629026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
    Artini PG; Monti M; Matteucci C; Valentino V; Cristello F; Genazzani AR
    Gynecol Endocrinol; 2006 Aug; 22(8):465-70. PubMed ID: 17012110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum retinol-binding protein-4 levels in polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in-vitro fertilization cycle.
    Orvieto R; Shuhat V; Liberty G; Homburg R; Anteby EY; Nahum R; Rabinson J; Meltcer S
    Clin Exp Obstet Gynecol; 2010; 37(2):100-4. PubMed ID: 21077495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial.
    Garcia-Velasco JA; Quea G; Piró M; Mayoral M; Ruiz M; Toribio M; Requena A
    Fertil Steril; 2009 Jul; 92(1):222-5. PubMed ID: 18710719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization.
    Kovacs P; Kovats T; Bernard A; Zadori J; Szmatona G; Kaali SG
    Fertil Steril; 2008 Dec; 90(6):2133-7. PubMed ID: 18177866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles.
    Lee TH; Liu CH; Huang CC; Wu YL; Shih YT; Ho HN; Yang YS; Lee MS
    Hum Reprod; 2008 Jan; 23(1):160-7. PubMed ID: 18000172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.